雾化吸入沙丁胺醇混悬液治疗哮喘患儿的临床研究  

Clinical trial of aerosolized in halation of salbutamol suspension in the treatment of children with asthma

作　　者：李敏[1] 汤昱[1] 赵二要[1] 张磊[1] 陈超辉[1] 乔俊英[2] 

机构地区：[1]郑州市儿童医院东区呼吸科,郑州450000 [2]郑州大学第三附属医院呼吸科,郑州450000

出　　处：《中国临床药理学杂志》2017年第19期1858-1861,共4页The Chinese Journal of Clinical Pharmacology

基　　金：河南省医学科技攻关项目计划基金资助项目(201304023)

摘　　要：目的观察雾化吸入沙丁胺醇治疗小儿哮喘的临床疗效及对患儿肺功能、血清嗜酸性粒细胞(EOS)、免疫球蛋白E(Ig E)的影响。方法将160例患儿随机分为试验组和对照组,各80例。对照组患儿雾化吸入布地奈德混悬液1.0mg,每次5 min,每天2次;试验组在对照组治疗之前给予沙丁胺醇溶液2.5 mg,每次5 min,每天2次,雾化吸入。2组患儿均治疗2周。比较2组患儿治疗前后及治疗后3个月的肺功能变化,观察治疗前后2组EOS、Ig E水平。结果治疗后,试验组总有效率为98.68%(75/76例),对照组为84.13%(53/63例),差异有统计学意义(P<0.05)。治疗后3个月,试验组和对照组用力肺活量(FVC)分别为(79.34±6.52),(70.20±3.34)L;第1秒用力通气量为(FEV1)分别为(80.12±3.32),(68.25±2.90)L;峰值呼气流速(PEF)分别为(82.08±9.62),(71.21±4.52)L·min-1;肺活量(VC)分别为(83.42±4.10),(73.17±2.34)L,差异均有统计学意义(均P<0.05)。试验组和对照组外周血EOS绝对值分别为(0.52±0.13)×109/L,(0.96±0.23)×109/L;血清Ig E水平分别为(105.32±62.35),(222.58±84.71)ng·m L-1,差异均有统计学意义(均P<0.05)。对照组出现恶心1例(1.59%),试验组出现声嘶2例(2.63%),2组均未出现药物过敏、院内感染、皮疹等药物不良反应,2组药物不良反应发生率差异无统计学意义(P>0.05)。结论糖皮质激素联合沙丁胺醇雾化吸入对小儿哮喘的临床疗效显著,且能明显降低血液EOS和Ig E水平,改善肺功能状态。Objective To evaluate the clinical efficacy of aerosolized inhalation of salbutamol suspension in the treatment of children with asthma and the influence of lung function, blood eosinophil（ EOS） and immunoglobulin E（ Ig E）. Methods A total of 160 children with asthma were randomly divided into treatment group（ n = 80 cases） and control group（ n = 80 cases）. The control group was treated with inhaled budesonide 1. 0 mg,5 min a time,twice a day,while the children in treatment group were treated combined with salbutamol 5 minutes a time,twice a day on the basis of control group. All patients were treated for 2weeks. The clinical efficacy in two groups were observed. The changes of blood EOS and Ig E at 3 months after treatment were observed. Results The total effective rate in treatment group was 98. 68%（ 75/76 cases）,had significant difference with that in control group,which was 84. 13%（ 53/63 cases,P〈0. 05）. And 3 months after treatment,the forced vital capacity（ FVC）,forced expiratory volume in first second（ FEV1）,peak expiratory flow（ PEF）,vital capacity（ VC） in treatment group were（ 79. 34 ± 6. 52） L,（ 80. 12 ± 3. 32） L,（ 82. 08 ± 9. 62） L·min^-1,（ 83. 42 ± 4. 10） L,had significant difference with those in control group,which were（ 70. 20 ± 3. 34） L,（ 68. 25 ± 2. 90） L,（ 71. 21 ± 4. 52） L·min^-1,（ 73. 17 ± 2. 34） L（ all P〈0. 05）. The absolute value of EOS and Ig E in treatment group were（ 0. 52 ± 0. 13）×10^9/L,（ 105. 32 ± 62. 35） ng·m L^-1,had significant difference with those in control group,which were（ 0. 96 ± 0. 23）×10^9/L,（ 222. 58 ± 84. 71） ng · m L-1（ all P〈0. 05）. The control group occurred 1 cases（ 1. 59%） of nausea,while treatment group occurred 2 cases（ 2. 63%）of hoarseness,with no significant difference（ P〈0. 05）. No drug allergy,nosocomial infections,rash and other adverse reactions occurred in two groups. Conclusion The application of glucocorticoid combined with s

关 键 词：糖皮质激素 沙丁胺醇 哮喘 血液嗜酸性粒细胞 免疫球蛋白E 肺功能 

分 类 号：R977.1[医药卫生—药品]